Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Myocardial DiseasesParvovirus B19, Human
Interventions
DRUG

Intravenous Immunoglobulins

2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days

DRUG

plasma volume expander

10 ml/kg BW will be administrated on four consecutive days.

Trial Locations (1)

6229 HX

AZM, Maastricht

Sponsors
All Listed Sponsors
lead

Prothya Biosolutions

INDUSTRY